For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
LPI (LP Information)' newest research report, the "BCG Vaccine Industry Forecast" looks at past sales and reviews total world BCG Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected BCG Vaccine sales for 2023 through 2029. With BCG Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BCG Vaccine industry.
This Insight Report provides a comprehensive analysis of the global BCG Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on BCG Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global BCG Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BCG Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BCG Vaccine.
The global BCG Vaccine market size is projected to grow from US$ 365.6 million in 2022 to US$ 542.8 million in 2029; it is expected to grow at a CAGR of 542.8 from 2023 to 2029.
Japan is the largest BCG Vaccine market with about 30% market share. North America is follower, accounting for about 29% market share.The key manufacturers are Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, GSBPL etc. Top 3 companies occupied about 77% market share.
This report presents a comprehensive overview, market shares, and growth opportunities of BCG Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Immune BCG
- Therapy BCG
Segmentation by application
- Hospitals
- Clinics
- Others
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Merck
- Sanofi Pasteur
- Japan BCG Lab
- China National Biotec
- Serum Institute of India
- Intervax
- GSBPL
Key Questions Addressed in this Report
What is the 10-year outlook for the global BCG Vaccine market?
What factors are driving BCG Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do BCG Vaccine market opportunities vary by end market size?
How does BCG Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?